PDSB SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Oncology Pipeline Highlights Tumor-Targeted Immunotherapies, Phase 2 Efficacy and Upcoming Clinical Readouts Across Solid Tumors

Oct 20, 2026

8-K

Three Pharma Industry Executives Join Board as Company Advances Cancer Immunotherapies Toward Phase 3 and Partnerships

Oct 20, 2026

8-K

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for Advanced Colorectal Cancer Treatment

Oct 6, 2026

8-K

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results for PDS0101 in JAMA Oncology

Sep 22, 2026

8-K

PDS Biotech Highlights Clinical Progress and Upcoming Catalysts for Oncology Drug Development Programs

Sep 21, 2026

8-K

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and Appointment of Dr. Patrick Soon-Shiong to Board of Directors

Sep 14, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Jul 21, 2026

424B5

[No Baby Shelf]* June 2026 ATM | Offering amount: $50,000,000 | Bank: Yorkville Securities, LLC and B. Riley Securities, Inc.

Jun 15, 2026

424B5

REGISTERED OFFERING

Nov 12, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 28, 2025

424B5

ATM | Offering amount: $50,000,000

Aug 13, 2024

424B5

SHELF OFFERING | Shares amount: 5,294,118 | Share price: $8.50 | Offering amount: $45,000,003.00

Jun 16, 2021

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 26, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jun 26, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jun 15, 2026

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

May 22, 2025

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

May 5, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Dawson John Andrew (Reporting)

Oct 21, 2026

Dawson John Andrew (Reporting)

Oct 21, 2026

Ramsdell Deborah (Reporting)

Oct 20, 2026

Wendel Bruce (Reporting)

Oct 20, 2026

Wendel Bruce (Reporting)

Oct 20, 2026

Ramsdell Deborah (Reporting)

Oct 20, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 22, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 29, 2026

CORRESP

Form CORRESP - Correspondence

Apr 24, 2026

LETTER

Form UPLOAD - SEC-generated letter

Sep 4, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 11, 2025

CORRESP

Form CORRESP - Correspondence

Jun 6, 2025

PDS Biotechnology Corporation PDSB · SEC Filings